Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Review Article

Anti-anxiety Properties of Selected Medicinal Plants

Author(s): Asmatullah Khan, Muhammad Akram, Muthu Thiruvengadam*, Muhammad Daniyal, Shahbaz Ahmad Zakki, Naveed Munir, Rida Zainab*, Mojtaba Heydari, Seyed Hamdollah Mosavat, Maksim Rebezov and Mohammad Ali Shariati

Volume 23, Issue 8, 2022

Published on: 14 January, 2022

Page: [1041 - 1060] Pages: 20

DOI: 10.2174/1389201022666210122125131

Price: $65

Open Access Journals Promotions 2
Abstract

Exploration of new drugs targeting anxiety treatment is a major concern worldwide. Medicinal plants are being used as a potential source of novel drugs for anxiety disorders. The objective of this review is to provide information about the healing outcomes of anxiety treatment with natural products. Valeriana officinalis, Citrus aurantium, Commelina benghalensis, Achyranthes aspera, Mimosa pudica, Achillea millefolium, Nymphaea alba, Leonurus cardiac, Camellia sinensis, Turnera aphrodisiaca, Crataegus oxyacantha and Piper methysticum showed promising effects on anxiety in animal models. In clinical studies, passion flower, kava, valerian, St John's wort, and hwagandha showed the most positive results. More studies are needed for the exploration of the antianxiety of medicinal plants. In drugs derived from natural sources have explored many components that are playing an essential role in curing anxiety disorders and associated complications.

Keywords: Anxiety, anti-anxiety agents, natural products, medicinal plant, traditional medicine, GABA.

Graphical Abstract
[1]
Roberts, R.E.; Duong, H.T. Is there an association between short sleep duration and adolescent anxiety disorders? Sleep Med., 2017, 30, 82-87.
[http://dx.doi.org/10.1016/j.sleep.2016.02.007] [PMID: 28215269]
[2]
Russell, W.D.; Cox, R.H. Social physique anxiety, body dissatisfaction, and self-esteem in college females of differing exercise frequency, perceived weight discrepancy, and race. J. Sport Behav., 2003, 26(3), 298-302.
[3]
Bandelow, B.; Michaelis, S.; Wedekind, D. Treatment of anxiety disorders. Dialogues Clin. Neurosci., 2017, 19(2), 93-107.
[http://dx.doi.org/10.31887/DCNS.2017.19.2/bbandelow] [PMID: 28867934]
[4]
Lim, L.; Goh, J.; Chan, Y.H.; Poon, S.H. Attitudes toward utility, effects and side effects of treatment for anxiety and depression. Australas. Psychiatry, 2016, 24(6), 556-560.
[http://dx.doi.org/10.1177/1039856216658828] [PMID: 27422741]
[5]
Nikfarjam, M.; Bahmani, M.; Heidari-Soureshjani, S. Phytotherapy for anxiety in Iran: a review of the most important anti-anxiety medicinal plants. J. Chem. Pharm. Sci., 2016, 9(3), 1235-1241.
[6]
Kurebayashi, L.F.; Turrini, R.N.; Kuba, G.; Shimizu, M.H.; Takiguch, R.S. Chinese phytotherapy to reduce stress, anxiety and improve quality of life: randomized controlled trial. Rev. Esc. Enferm. USP, 2016, 50(5), 853-860.
[http://dx.doi.org/10.1590/s0080-623420160000600020] [PMID: 27982406]
[7]
Wittchen, H.U. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress. Anxiety, 2002, 16(4), 162-171.
[http://dx.doi.org/10.1002/da.10065] [PMID: 12497648]
[8]
Mullick, M.S.; Goodman, R. The prevalence of psychiatric disorders among 5-10 year olds in rural, urban and slum areas in Bangladesh: an exploratory study. Soc. Psychiatry Psychiatr. Epidemiol., 2005, 40(8), 663-671.
[http://dx.doi.org/10.1007/s00127-005-0939-5] [PMID: 16091858]
[9]
Craske, M.G.; Rauch, S.L.; Ursano, R.; Prenoveau, J.; Pine, D.S.; Zinbarg, R.E. What is an anxiety disorder? Depress. Anxiety, 2009, 26(12), 1066-1085.
[http://dx.doi.org/10.1002/da.20633] [PMID: 19957279]
[10]
Brook, C.A.; Schmidt, L.A. Social anxiety disorder: a review of environmental risk factors. Neuropsychiatr. Dis. Treat., 2008, 4(1), 123-143.
[PMID: 18728768]
[11]
Gosselin, P.; Laberge, B. Etiological factors of generalized anxiety disorder. Encephale, 2003, 29(4 Pt 1), 351-361.
[PMID: 14615705]
[12]
Lobão-Soares, B.; Walz, R.; Carlotti, C.G., Jr; Sakamoto, A.C.; Calvo, F.; Terzian, A.L.B.; da Silva, J.A.; Wichert-Ana, L.; Coimbra, N.C.; Bianchin, M.M. Cellular prion protein regulates the motor behaviour performance and anxiety-induced responses in genetically modified mice. Behav. Brain Res., 2007, 183(1), 87-94.
[http://dx.doi.org/10.1016/j.bbr.2007.05.027] [PMID: 17618696]
[13]
Nutt, D.J.; Ballenger, J.C.; Sheehan, D.; Wittchen, H.U. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int. J. Neuropsychopharmacol., 2002, 5(4), 315-325.
[http://dx.doi.org/10.1017/S1461145702003048] [PMID: 12466031]
[14]
Tyrer, P.; Baldwin, D. Generalised anxiety disorder. Lancet, 2006, 368(9553), 2156-2166.
[http://dx.doi.org/10.1016/S0140-6736(06)69865-6] [PMID: 17174708]
[15]
Gelenberg, A.J. Psychiatric and somatic markers of anxiety: identification and pharmacologic treatment. Prim. Care Companion J. Clin. Psychiatry, 2000, 2(2), 49-54.
[http://dx.doi.org/10.4088/PCC.v02n0204] [PMID: 15014583]
[16]
Bonjardim, L.R.; Gavião, M.B.; Pereira, L.J.; Castelo, P.M. Anxiety and depression in adolescents and their relationship with signs and symptoms of temporomandibular disorders. Int. J. Prosthodont., 2005, 18(4), 347-352.
[PMID: 16052791]
[17]
Yeung, K.S.; Hernandez, M.; Mao, J.J.; Haviland, I.; Gubili, J. Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance. Phytother. Res., 2018, 32(5), 865-891.
[http://dx.doi.org/10.1002/ptr.6033] [PMID: 29464801]
[18]
Saki, K.; Bahmani, M.; Rafieian-Kopaei, M. The effect of most important medicinal plants on two importnt psychiatric disorders (anxiety and depression)-a review. Asian Pac. J. Trop. Med., 2014, 7S1, S34-S42.
[http://dx.doi.org/10.1016/S1995-7645(14)60201-7] [PMID: 25312147]
[19]
Abubakar, A.R.; Haque, M. Medicinal plants with reported anxiolytic and sedative activities in Nigeria: a systematic review. Istanb. J. Pharm., 2019, 49(2), 92-104.
[http://dx.doi.org/10.26650/IstanbulJPharm.2019.18008]
[20]
Coimbra, N.C.; Paschoalin-Maurin, T.; Bassi, G.S.; Kanashiro, A.; Biagioni, A.F.; Felippotti, T.T.; Elias-Filho, D.H.; Mendes-Gomes, J.; Cysne-Coimbra, J.P.; Almada, R.C.; Lobão-Soares, B. Critical neuropsychobiological analysis of panic attack- and anticipatory anxiety-like behaviors in rodents confronted with snakes in polygonal arenas and complex labyrinths: a comparison to the elevated plus- and T-maze behavioral tests. Br. J. Psychiatry, 2017, 39(1), 72-83.
[http://dx.doi.org/10.1590/1516-4446-2015-1895] [PMID: 28177062]
[21]
Fajemiroye, J.O.; da Silva, D.M.; de Oliveira, D.R.; Costa, E.A. Treatment of anxiety and depression: medicinal plants in retrospect. Fundam. Clin. Pharmacol., 2016, 30(3), 198-215.
[http://dx.doi.org/10.1111/fcp.12186] [PMID: 26851117]
[22]
Pelletier, K.R.; Marie, A.; Krasner, M.; Haskell, W.L. Current trends in the integration and reimbursement of complementary and alternative medicine by managed care, insurance carriers, and hospital providers. Am. J. Health Promot., 1997, 12(2), 112-122.
[http://dx.doi.org/10.4278/0890-1171-12.2.112] [PMID: 10174663]
[23]
Head, K.A.; Kelly, G.S. Nutrients and botanicals for treatment of stress: adrenal fatigue, neurotransmitter imbalance, anxiety, and restless sleep. Altern. Med. Rev., 2009, 14(2), 114-140.
[PMID: 19594222]
[24]
Miller, L.G. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch. Intern. Med., 1998, 158(20), 2200-2211.
[http://dx.doi.org/10.1001/archinte.158.20.2200] [PMID: 9818800]
[25]
Olatunji, B.O.; Cisler, J.M.; Deacon, B.J. Efficacy of cognitive behavioral therapy for anxiety disorders: a review of meta-analytic findings. Psychiatr. Clin. North Am., 2010, 33(3), 557-577.
[http://dx.doi.org/10.1016/j.psc.2010.04.002] [PMID: 20599133]
[26]
Waller, R.; Gilbody, S. Barriers to the uptake of computerized cognitive behavioural therapy: a systematic review of the quantitative and qualitative evidence. Psychol. Med., 2009, 39(5), 705-712.
[http://dx.doi.org/10.1017/S0033291708004224] [PMID: 18812006]
[27]
Butler, A.C.; Chapman, J.E.; Forman, E.M.; Beck, A.T. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin. Psychol. Rev., 2006, 26(1), 17-31.
[http://dx.doi.org/10.1016/j.cpr.2005.07.003] [PMID: 16199119]
[28]
Ravindran, L.N.; Stein, M.B. The pharmacologic treatment of anxiety disorders: a review of progress. J. Clin. Psychiatry, 2010, 71(7), 839-854.
[http://dx.doi.org/10.4088/JCP.10r06218blu] [PMID: 20667290]
[29]
Cloos, J.M.; Ferreira, V. Current use of benzodiazepines in anxiety disorders. Curr. Opin. Psychiatry, 2009, 22(1), 90-95.
[http://dx.doi.org/10.1097/YCO.0b013e32831a473d] [PMID: 19122540]
[30]
Campo-Soria, C.; Chang, Y.; Weiss, D.S. Mechanism of action of benzodiazepines on GABAA receptors. Br. J. Pharmacol., 2006, 148(7), 984-990.
[http://dx.doi.org/10.1038/sj.bjp.0706796] [PMID: 16783415]
[31]
Rudolph, U.; Knoflach, F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov., 2011, 10(9), 685-697.
[http://dx.doi.org/10.1038/nrd3502] [PMID: 21799515]
[32]
Ballenger, J.C. Anxiety and depression: optimizing treatments. Prim. Care Companion J. Clin. Psychiatry, 2000, 2(3), 71-79.
[http://dx.doi.org/10.4088/PCC.v02n0301] [PMID: 15014652]
[33]
Ferguson, J.M. SSRI antidepressant medications: adverse effects and tolerability. Prim. Care Companion J. Clin. Psychiatry, 2001, 3(1), 22-27.
[http://dx.doi.org/10.4088/PCC.v03n0105] [PMID: 15014625]
[34]
Steenen, S.A.; van Wijk, A.J.; van der Heijden, G.J.; van Westrhenen, R.; de Lange, J.; de Jongh, A. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J. Psychopharmacol., 2016, 30(2), 128-139.
[http://dx.doi.org/10.1177/0269881115612236] [PMID: 26487439]
[35]
Zohar, J.; Westenberg, H.G. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. Suppl., 2000, 403(403), 39-49.
[http://dx.doi.org/10.1111/j.1600-0447.2000.tb10947.x] [PMID: 11019934]
[36]
Gillman, P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br. J. Pharmacol., 2007, 151(6), 737-748.
[http://dx.doi.org/10.1038/sj.bjp.0707253] [PMID: 17471183]
[37]
Fiedorowicz, J.G.; Swartz, K.L. The role of monoamine oxidase inhibitors in current psychiatric practice. J. Psychiatr. Pract., 2004, 10(4), 239-248.
[http://dx.doi.org/10.1097/00131746-200407000-00005] [PMID: 15552546]
[38]
McRae, A.L.; Sonne, S.C.; Brady, K.T.; Durkalski, V.; Palesch, Y. A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals. Am. J. Addict., 2004, 13(1), 53-63.
[http://dx.doi.org/10.1080/10550490490265325] [PMID: 14766438]
[39]
Roncon, C.M.; Biesdorf, C.; Coimbra, N.C.; Audi, E.A.; Zangrossi, H., Jr; Graeff, F.G. Cooperative regulation of anxiety and panic-related defensive behaviors in the rat periaqueductal grey matter by 5-HT1A and μ-receptors. J. Psychopharmacol., 2013, 27(12), 1141-1148.
[http://dx.doi.org/10.1177/0269881113485144] [PMID: 23598399]
[40]
Spiacci, A., Jr; Coimbra, N.C.; Zangrossi, H., Jr Differential involvement of dorsal raphe subnuclei in the regulation of anxiety- and panic-related defensive behaviors. Neuroscience, 2012, 227, 350-360.
[http://dx.doi.org/10.1016/j.neuroscience.2012.09.061] [PMID: 23041762]
[41]
Netto, S.M.; Silveira, R.; Coimbra, N.C.; Joca, S.R.; Guimarães, F.S. Anxiogenic effect of median raphe nucleus lesion in stressed rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2002, 26(6), 1135-1141.
[http://dx.doi.org/10.1016/S0278-5846(02)00248-8] [PMID: 12452536]
[42]
Kessler, R.C.; Soukup, J.; Davis, R.B.; Foster, D.F.; Wilkey, S.A.; Van Rompay, M.I.; Eisenberg, D.M. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am. J. Psychiatry, 2001, 158(2), 289-294.
[http://dx.doi.org/10.1176/appi.ajp.158.2.289] [PMID: 11156813]
[43]
Ekor, M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol., 2014, 4, 177.
[http://dx.doi.org/10.3389/fphar.2013.00177] [PMID: 24454289]
[44]
Birari, R.B.; Bhutani, K.K. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov. Today, 2007, 12(19-20), 879-889.
[http://dx.doi.org/10.1016/j.drudis.2007.07.024] [PMID: 17933690]
[45]
Sarris, J.; Kavanagh, D.J.; Deed, G.; Bone, K.M.St. John’s wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. Hum. Psychopharmacol., 2009, 24(1), 41-48.
[http://dx.doi.org/10.1002/hup.994] [PMID: 19090505]
[46]
Sarris, J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother. Res., 2007, 21(8), 703-716.
[http://dx.doi.org/10.1002/ptr.2187] [PMID: 17562566]
[47]
Kumar, V. Potential medicinal plants for CNS disorders: an overview. Phytother. Res., 2006, 20(12), 1023-1035.
[http://dx.doi.org/10.1002/ptr.1970] [PMID: 16909441]
[48]
Boonen, G.; Häberlein, H. Influence of genuine kavapyrone enantiomers on the GABA-A binding site. Planta Med., 1998, 64(6), 504-506.
[http://dx.doi.org/10.1055/s-2006-957502] [PMID: 9776662]
[49]
Chen, H.W.; Chen, L.; Li, B.; Yin, H.L.; Tian, Y.; Wang, Q.; Xiao, Y.H.; Dong, J.X. Three new germacrane-type sesquiterpenes with NGF-potentiating activity from Valeriana officinalis var. latiofolia. Molecules, 2013, 18(11), 14138-14147.
[http://dx.doi.org/10.3390/molecules181114138] [PMID: 24241156]
[50]
Kapoor, V.K.; Dureja, J.; Chadha, R. Herbals in the control of ageing. Drug Discov. Today, 2009, 14(19-20), 992-998.
[http://dx.doi.org/10.1016/j.drudis.2009.06.014] [PMID: 19596462]
[51]
Patočka, J.; Jakl, J. Biomedically relevant chemical constituents of Valeriana officinalis. J. Appl. Biomed., 2010, 8(1), 11-18.
[http://dx.doi.org/10.2478/v10136-009-0002-z]
[52]
Valle-Mojica, D.; Lisa, M.; Ayala-Marín, Y.M.; Ortiz-Sanchez, C.M.; Torres-Hernández, B.A.; Abdalla-Mukhaimer, S. Selective interactions of Valeriana officinalis extracts and valerenic acid with 3H glutamate binding to rat synaptic membranes. Evid. Based Complement. Alternat. Med., 2011, 201(1), 1-8.
[http://dx.doi.org/10.1155/2011/403591]
[53]
Farah, G.J.; Ferreira, G.Z.; Danieletto-Zanna, C.F.; Luppi, C.R.; Jacomacci, W.P. Assessment of Valeriana officinalis L.(Valerian) for conscious sedation of patients during the extraction of impacted mandibular third molars: a randomized, split-mouth, double-blind, crossover study. J. Oral Maxillofac. Surg., 2019, 77(9), 1796.e1-1796.e8.
[http://dx.doi.org/10.1016/j.joms.2019.05.003] [PMID: 31158346]
[54]
Occhiuto, F.; Pino, A.; Palumbo, D.R.; Samperi, S.; De Pasquale, R.; Sturlese, E.; Circosta, C. Relaxing effects of Valeriana officinalis extracts on isolated human non-pregnant uterine muscle. J. Pharm. Pharmacol., 2009, 61(2), 251-256.
[http://dx.doi.org/10.1211/jpp.61.02.0016] [PMID: 19178774]
[55]
Kennedy, D.O.; Little, W.; Haskell, C.F.; Scholey, A.B. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother. Res., 2006, 20(2), 96-102.
[http://dx.doi.org/10.1002/ptr.1787] [PMID: 16444660]
[56]
Hattesohl, M.; Feistel, B.; Sievers, H.; Lehnfeld, R.; Hegger, M.; Winterhoff, H. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine, 2008, 15(1-2), 2-15.
[http://dx.doi.org/10.1016/j.phymed.2007.11.027] [PMID: 18160026]
[57]
Moore, G.A. Oranges and lemons: clues to the taxonomy of Citrus from molecular markers. Trends Genet., 2001, 17(9), 536-540.
[http://dx.doi.org/10.1016/S0168-9525(01)02442-8] [PMID: 11525837]
[58]
Kim, G.S.; Park, H.J.; Woo, J.H.; Kim, M.K.; Koh, P.O.; Min, W.; Ko, Y.G.; Kim, C.H.; Won, C.K.; Cho, J.H. Citrus aurantium flavonoids inhibit adipogenesis through the Akt signaling pathway in 3T3-L1 cells. BMC Complement. Altern. Med., 2012, 12(1), 31-34.
[http://dx.doi.org/10.1186/1472-6882-12-31] [PMID: 22471389]
[59]
Rouseff, R.L.; Martin, S.F.; Youtsey, C.O. Quantitative survey of narirutin, naringin, hesperidin, and neohesperidin in citrus. J. Agric. Food Chem., 1987, 35(6), 1027-1030.
[http://dx.doi.org/10.1021/jf00078a040]
[60]
Jayaprakasha, G.K.; Mandadi, K.K.; Poulose, S.M.; Jadegoud, Y.; Nagana Gowda, G.A.; Patil, B.S. Novel triterpenoid from Citrus aurantium L. possesses chemopreventive properties against human colon cancer cells. Bioorg. Med. Chem., 2008, 16(11), 5939-5951.
[http://dx.doi.org/10.1016/j.bmc.2008.04.063] [PMID: 18490169]
[61]
Colker, C.M.; Kaiman, D.S.; Torina, G.C.; Perlis, T.; Street, C. Effects of Citrus aurantium extract, caffeine, and St. John’s wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr. Ther. Res. Clin. Exp., 1999, 60(3), 145-153.
[http://dx.doi.org/10.1016/S0011-393X(00)88523-9]
[62]
Calapai, G.; Firenzuoli, F.; Saitta, A.; Squadrito, F.; Arlotta, M.R.; Costantino, G. Antiobesity and cardiovascular toxic effects of Citrus aurantium extracts in the rat: a preliminary report. Fitoterapia, 1999, 70(6), 586-592.
[http://dx.doi.org/10.1016/S0367-326X(99)00093-3]
[63]
Karthikeyan, V.; Karthikeyan, J. Citrus aurantium (bitter orange): A review of its traditional uses, phytochemistry and pharmacology. Int. J. Discov. Herb. Res., 2014, 4(4), 766-772.
[64]
Suntar, I. Khan, H.; Patel, S.; Celano, R.; Rastrelli, L. An overview on Citrus aurantium L.: its functions as food ingredient and therapeutic agent. Oxid. Med. Cell. Longev., 2018, 7(8), 64-70.
[65]
Akhlaghi, M.; Shabanian, G.; Rafieian-Kopaei, M.; Parvin, N.; Saadat, M.; Akhlaghi, M. Citrus aurantium blossom and preoperative anxiety. Rev. Bras. Anestesiol., 2011, 61(6), 702-712.
[http://dx.doi.org/10.1016/S0034-7094(11)70079-4] [PMID: 22063371]
[66]
Costa, C.A.; Cury, T.C.; Cassettari, B.O.; Takahira, R.K.; Flório, J.C.; Costa, M. Citrus aurantium L. essential oil exhibits anxiolytic-like activity mediated by 5-HT(1A)-receptors and reduces cholesterol after repeated oral treatment. BMC Complement. Altern. Med., 2013, 13(1), 42-50.
[http://dx.doi.org/10.1186/1472-6882-13-42] [PMID: 23432968]
[67]
Chaves Neto, G.; Braga, J.E.F.; Alves, M.F.; de Morais Pordeus, L.C.; Dos Santos, S.G.; Scotti, M.T.; Almeida, R.N.; Diniz, M.F.F.M. Anxiolytic effect of Citrus aurantium L. in crack users. Evid. Based Complement. Alternat. Med., 2017, 2017(8), 7217619.
[http://dx.doi.org/10.1155/2017/7217619] [PMID: 29234424]
[68]
Mannucci, C.; Calapai, F.; Cardia, L.; Inferrera, G.D. ’Arena, G.D.; Pietro, M. Clinical pharmacology of Citrus aurantium and Citrus sinensis for the treatment of anxiety. Evid. Based Complement. Alternat. Med., 2018, 3(6), 94-98.
[69]
Carvalho-Freitas, M.I.; Costa, M. Anxiolytic and sedative effects of extracts and essential oil from Citrus aurantium L. Biol. Pharm. Bull., 2002, 25(12), 1629-1633.
[http://dx.doi.org/10.1248/bpb.25.1629] [PMID: 12499653]
[70]
Pultrini, A.M.; Galindo, L.A.; Costa, M. Effects of the essential oil from Citrus aurantium L. in experimental anxiety models in mice. Life Sci., 2006, 78(15), 1720-1725.
[http://dx.doi.org/10.1016/j.lfs.2005.08.004] [PMID: 16253279]
[71]
Ghosh, P.; Dutta, A.; Biswas, M.; Biswas, S.; Hazra, L.; Nag, S.K. Phytomorphological, chemical and pharmacological discussions about Commelina benghalensis Linn. (Commelinaceae): a review. J. Pharm. Innov., 2019, 8(6), 12-18.
[72]
Orni, P.R.; Shetu, H.J.; Khan, T.; Rashed, S.S.; Dash, P.R. A comprehensive review on Commelina benghalensis L.(Commelinaceae). Inter. J. Pharmacog., 2018, 5(10), 637-645.
[73]
Nabi, B.; Rehman, S.; Baboota, S.; Ali, J. Natural antileprotic agents: a boon for the management of leprosy. Discov. Develop. Therapeut. Nat. Prod. Neglec. Trop. Dis, 2001, 351-372.
[74]
Ibrahim, J.; Ajaegbu, V.C.; Egharevba, H.O. Pharmacognostic and phytochemical analysis of Commelina benghalensis L. Ethnobot. Leaflets, 2010, 2010(5), 610-615.
[75]
Hasan, S.R.; Hossain, M.; Akter, R.; Jamila, M.; Mazumder, M.; Alam, M. Analgesic activity of the different fractions of the aerial parts of Commelina benghalensis Linn. Int. J. Pharm., 2010, 6(1), 63-67.
[http://dx.doi.org/10.3923/ijp.2010.63.67]
[76]
Lebogo, K.W.; Mokgotho, M.P.; Bagla, V.P.; Matsebatlela, T.M.; Mbazima, V.; Shai, L.J.; Mampuru, L. Semi-purified extracts of Commelina benghalensis (Commelinaceae) induce apoptosis and cell cycle arrest in Jurkat-T cells. BMC Complement. Altern. Med., 2014, 14(1), 65-70.
[http://dx.doi.org/10.1186/1472-6882-14-65] [PMID: 24555704]
[77]
Mbazima, V.G.; Mokgotho, M.P.; February, F.; Rees, D.J.; Mampuru, L. Alteration of Bax-to-Bcl-2 ratio modulates the anticancer activity of methanolic extract of Commelina benghalensis (Commelinaceae) in Jurkat T cells. Afr. J. Biotechnol., 2008, 7(20), 3569-3576.
[78]
Hasan, S.; Hossain, M.; Faruque, A.; Mazumder, M.; Rana, M.; Akter, R. Comparison of antioxidant potential of different fractions of Commelina benghalensis Linn. Bangl. J. Life Sci., 2008, 20(2), 9-16.
[79]
Raquibul Hasan, S.M.; Hossain, M.M.; Akter, R.; Jamila, M.; Mazumder, E.H.; Rahman, S. Sedative and anxiolytic effects of different fractions of the Commelina benghalensis Linn. Drug Discov. Ther., 2009, 3(5), 221-227.
[PMID: 22495632]
[80]
Chakrabarty, N.; Chowdhury, T.A.; Shoibe, M.; Kabir, M.S.; Hasan, M.N.; Chowdhury, M.H. antidepressant activity of methanol extract of Commelina bengjalensis Linn. Whole plant. World J. Pharm. Res., 2016, 5(7), 1726-1733.
[81]
Chakraborty, A.; Brantner, A.; Mukainaka, T.; Nobukuni, Y.; Kuchide, M.; Konoshima, T.; Tokuda, H.; Nishino, H. Cancer chemopreventive activity of Achyranthes aspera leaves on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. Cancer Lett., 2002, 177(1), 1-5.
[http://dx.doi.org/10.1016/S0304-3835(01)00766-2] [PMID: 11809524]
[82]
Singh, S.; Singh, A.; Navneet, S.V. Ethnobotanical and pharmacological benefits of Achyranthes aspera Linn.: an overview. Int. J. Pharm. Sci. Rev. Res., 2018, 48(2), 1-7.
[83]
Ghimire, K.; Banerjee, J.; Gupta, A.K.; Dahal, P. Phytochemical constituents and pharmacological uses of medicinal plant Achyranthes aspera: a review. World J. Pharm. Res., 2014, 4(1), 470-489.
[84]
Dange, S.; Patki, P.; Pawar, S.; Phadke, S.; Shrotri, D. Comparative efficacy of five indigenous compound formulations in patients of acute viral hepatitis. Maharashtra Med. J., 1989, 36, 75-80.
[85]
Akhtar, M.S.; Iqbal, J. Evaluation of the hypoglycaemic effect of Achyranthes aspera in normal and alloxan-diabetic rabbits. J. Ethnopharmacol., 1991, 31(1), 49-57.
[http://dx.doi.org/10.1016/0378-8741(91)90143-2] [PMID: 2030593]
[86]
Srivastav, S.; Singh, P.; Mishra, G.; Jha, K.; Khosa, R. Achyranthes aspera-An important medicinal plant: a review. Nat. Prod. Plant Resources, 2005, 6(1), 5-7.
[87]
Sujitha, K.; Sri, A.P.; Rao, P.; Lal, M.; Srinivasarao, K.; Sree, V.K. Preliminary screening of Syzygium cumini and Achyranthes aspera for their anthelmintic activity. Res. J. Pharmacog. Phytochem., 2010, 2(6), 445-449.
[88]
Rani, N.; Sharma, S.K.; Vasudeva, N. Assessment of antiobesity potential of Achyranthes aspera Linn. seed. Evid. Based Complement. Alternat. Med., 2012, 2012(15), 715912.
[PMID: 22919417]
[89]
Priya, C.; Kumar, G.; Karthik, L.K.V. B.R. Phytochemical composition and in vitro antioxidant activity of Achyranthes aspera Linn (Amaranthaceae) leaf extracts. Agric. Technol. Thail., 2012, 8(1), 143-156.
[90]
Vasudeva, R.Y.; Duddukuri, G.R.; Sunil, B.G.; Athota, R.R. Immunomodulatory activity of Achyranthes aspera on the elicitation of antigen-specific murine antibody response. Pharm. Biol., 2002, 40(3), 175-178.
[http://dx.doi.org/10.1076/phbi.40.3.175.5831]
[91]
Bagavan, A.; Rahuman, A.A.; Kamaraj, C.; Geetha, K. Larvicidal activity of saponin from Achyranthes aspera against Aedes aegypti and Culex quinquefasciatus (Diptera: Culicidae). Parasitol. Res., 2008, 103(1), 223-229.
[http://dx.doi.org/10.1007/s00436-008-0962-z] [PMID: 18392726]
[92]
Vijaya Kumar, S.; Sankar, P.; Varatharajan, R. Anti-inflammatory activity of roots of Achyranthes aspera. Pharm. Biol., 2009, 47(10), 973-975.
[http://dx.doi.org/10.1080/13880200902967979]
[93]
Vasudeva Rao, Y.; Das, B.K.; Jyotyrmayee, P.; Chakrabarti, R. Effect of Achyranthes aspera on the immunity and survival of Labeo rohita infected with Aeromonas hydrophila. Fish Shellfish Immunol., 2006, 20(3), 263-273.
[http://dx.doi.org/10.1016/j.fsi.2005.04.006] [PMID: 15961319]
[94]
Barua, C.C.; Talukdar, A.; Begum, S.A.; Borah, P.; Lahkar, M. Anxiolytic activity of methanol leaf extract of Achyranthes aspera Linn in mice using experimental models of anxiety. Indian J. Pharmacol., 2012, 44(1), 63-67.
[http://dx.doi.org/10.4103/0253-7613.91869] [PMID: 22345872]
[95]
Barua, C.; Begum, S.; Talukdar, A.; Pathak, D.; Barua, A.; Borah, P. Effect of Achyranthes aspera Linn on modified forced swimming in rats. Pharmacol. Online, 2010, 5(4), 183-191.
[96]
Vismayaviswan, T.; Dharani, J.; Sripathi, R.; Ravi, S. composition of the essential oil from Mimosa pudica linn. Asian J. Pharm. Clin. Res., 2019, 12(3), 170-172.
[97]
Muhammad, G.; Hussain, M.A.; Jantan, I.; Bukhari, S.N.A. Bukhari, S.N.; Mimosa pudica, L. a high‐value medicinal plant as a source of bioactives for pharmaceuticals. Compr. Rev. Food Sci. Food Saf., 2016, 15(2), 303-315.
[http://dx.doi.org/10.1111/1541-4337.12184] [PMID: 33371596]
[98]
Joseph, B.; George, J.; Mohan, J. Pharmacology and traditional uses of Mimosa pudica. Int. J. Pharm. Sci. Rev. Drug Res., 2013, 5(2), 41-44.
[99]
Yang, E.J.; Lee, J.S.; Yun, C.Y.; Ryang, Y.S.; Kim, J.B.; Kim, I.S. Suppression of ovalbumin-induced airway inflammatory responses in a mouse model of asthma by Mimosa pudica extract. Phytother. Res., 2011, 25(1), 59-66.
[http://dx.doi.org/10.1002/ptr.3220] [PMID: 20623591]
[100]
Solanki, R. In-vitro antileprotic activity of ethanolic extracts of Mimosa Pudica L. and Prosopis cineraria L. (Druce). Int. J. Sci. Res. (Ahmedabad), 2016, 4(12), 508-509.
[101]
Ganguly, M.; Devi, N.; Mahanta, R.; Borthakur, M.K. Effect of Mimosa pudica root extract on vaginal estrous and serum hormones for screening of antifertility activity in albino mice. Contraception, 2007, 76(6), 482-485.
[http://dx.doi.org/10.1016/j.contraception.2007.08.008] [PMID: 18061708]
[102]
Sohil, V.; Sundaram, R.M. Hepatoprotective activity of Mimosa pudica leaves against Carbon tetrachloride induced toxicity. J. Nat. Prod., 2009, 2009(2), 116-122.
[103]
Vikram, P.K.; Malvi, R.; Jain, D.K. Evaluation of analgesic and anti-inflammatory potential of Mimosa pudica Linn. Int. J. Curr. Pharm. Res., 2012, 4(4), 47-50.
[104]
Ahmad, H.; Sehgal, S.; Mishra, A.; Gupta, R. Mimosa pudica L. (Laajvanti): an overview. Pharmacogn. Rev., 2012, 6(12), 115-124.
[http://dx.doi.org/10.4103/0973-7847.99945] [PMID: 23055637]
[105]
Molina, M.; Contreras, C.M.; Tellez-Alcantara, P. Mimosa pudica may possess antidepressant actions in the rat. Phytomedicine, 1999, 6(5), 319-323.
[http://dx.doi.org/10.1016/S0944-7113(99)80052-X] [PMID: 11962537]
[106]
Kokane, D.D.; More, R.Y.; Kale, M.B.; Nehete, M.N.; Mehendale, P.C.; Gadgoli, C.H. Evaluation of wound healing activity of root of Mimosa pudica. J. Ethnopharmacol., 2009, 124(2), 311-315.
[http://dx.doi.org/10.1016/j.jep.2009.04.038] [PMID: 19397984]
[107]
Meenatchisundaram, S.; Priyagrace, S.; Vijayaraghavan, R.; Velmurugan, A.; Parameswari, G.; Michael, A. Antitoxin activity of Mimosa pudica root extracts against Naja naja and Bangarus caerulus venoms. Bangladesh J. Pharmacol., 2009, 4(2), 105-109.
[http://dx.doi.org/10.3329/bjp.v4i2.2276]
[108]
Zhang, J.; Yuan, K.; Zhou, W.L.; Zhou, J.; Yang, P. Studies on the active components and antioxidant activities of the extracts of Mimosa pudica Linn. from southern China. Pharmacogn. Mag., 2011, 7(25), 35-39.
[http://dx.doi.org/10.4103/0973-1296.75899] [PMID: 21472077]
[109]
Rajendran, R.; Krishnakumar, E. Hypolipidemic activity of chloroform extract of Mimosa pudica leaves. Avicenna J. Med. Biotechnol., 2010, 2(4), 215-221.
[PMID: 23408779]
[110]
Sutar, N.; Sutar, U.; Behera, B. Antidiabetic activity of the leaves of Mimosa pudica Linn. in albino rats. J. Herb. Med. Toxicol., 2009, 3(1), 123-126.
[111]
Ngo Bum, E.; Dawack, D.L.; Schmutz, M.; Rakotonirina, A.; Rakotonirina, S.V.; Portet, C.; Jeker, A.; Olpe, H.R.; Herrling, P. Anticonvulsant activity of Mimosa pudica decoction. Fitoterapia, 2004, 75(3-4), 309-314.
[http://dx.doi.org/10.1016/j.fitote.2004.01.012] [PMID: 15158987]
[112]
Shaikh, Z.; Roy, S.P.; Patel, P.; Gohil, K. Medicinal value of Mimosa pudica as an anxiolytic and antidepressant: A comprehensive review. World J. Pharm. Pharm. Sci., 2016, 5(3), 420-430.
[113]
Patro, G.; Kumar Bhattamisra, S.; Kumar Mohanty, B. Effects of Mimosa pudica L. leaves extract on anxiety, depression and memory. Avicenna J. Phytomed., 2016, 6(6), 696-710.
[PMID: 28078250]
[114]
Ayissi Mbomo, R.; Gartside, S.; Ngo Bum, E.; Njikam, N.; Okello, E.; McQuade, R. Effect of Mimosa pudica (Linn.) extract on anxiety behaviour and GABAergic regulation of 5-HT neuronal activity in the mouse. J. Psychopharmacol., 2012, 26(4), 575-583.
[http://dx.doi.org/10.1177/0269881111398686] [PMID: 21427203]
[115]
Saeidnia, S.; Gohari, A.; Mokhber-Dezfuli, N.; Kiuchi, F. A review on phytochemistry and medicinal properties of the genus Achillea. Daru, 2011, 19(3), 173-186.
[PMID: 22615655]
[116]
Nemeth, E.; Bernath, J. Biological activities of yarrow species (Achillea spp.). Curr. Pharm. Des., 2008, 14(29), 3151-3167.
[http://dx.doi.org/10.2174/138161208786404281] [PMID: 19075697]
[117]
Applequist, W.L.; Moerman, D.E. Yarrow, (Achillea millefolium L.): A Neglected Panacea? A review of ethnobotany, bioactivity, and biomedical research. Econ. Bot., 2011, 65(2), 209-225.
[http://dx.doi.org/10.1007/s12231-011-9154-3]
[118]
Khan, A.U.; Gilani, A.H. Blood pressure lowering, cardiovascular inhibitory and bronchodilatory actions of Achillea millefolium. Phytother. Res., 2011, 25(4), 577-583.
[http://dx.doi.org/10.1002/ptr.3303] [PMID: 20857434]
[119]
Yaeesh, S.; Jamal, Q.; Khan, A.U.; Gilani, A.H. Studies on hepatoprotective, antispasmodic and calcium antagonist activities of the aqueous-methanol extract of Achillea millefolium. Phytother. Res., 2006, 20(7), 546-551.
[http://dx.doi.org/10.1002/ptr.1897] [PMID: 16619341]
[120]
Tuberoso, C.I.; Kowalczyk, A.; Coroneo, V.; Russo, M.T.; Dessì, S.; Cabras, P. Chemical composition and antioxidant, antimicrobial, and antifungal activities of the essential oil of Achillea ligustica all. J. Agric. Food Chem., 2005, 53(26), 10148-10153.
[http://dx.doi.org/10.1021/jf0518913] [PMID: 16366708]
[121]
Trouillas, P.; Calliste, C.A.; Allais, D.P.; Simon, A.; Marfak, A.; Delage, C. Antioxidant, anti-inflammatory and antiproliferative properties of sixteen water plant extracts used in the Limousin countryside as herbal teas. Food Chem., 2003, 80(3), 399-407.
[http://dx.doi.org/10.1016/S0308-8146(02)00282-0]
[122]
Bezić, N.; Skocibusić, M.; Dunkić, V.; Radonić, A. Composition and antimicrobial activity of Achillea clavennae L. essential oil. Phytother. Res., 2003, 17(9), 1037-1040.
[http://dx.doi.org/10.1002/ptr.1290] [PMID: 14595583]
[123]
Moradi, M.T.; Rafieian-Koupaei, M.; Imani-Rastabi, R.; Nasiri, J.; Shahrani, M.; Rabiei, Z.; Alibabaei, Z. Antispasmodic effects of yarrow (Achillea millefolium L.) extract in the isolated ileum of rat. Afr. J. Tradit. Complement. Altern. Med., 2013, 10(6), 499-503.
[http://dx.doi.org/10.4314/ajtcam.v10i6.19] [PMID: 24311877]
[124]
Candan, F.; Unlu, M.; Tepe, B.; Daferera, D.; Polissiou, M.; Sökmen, A.; Akpulat, H.A. Antioxidant and antimicrobial activity of the essential oil and methanol extracts of Achillea millefolium subsp. millefolium Afan. (Asteraceae). J. Ethnopharmacol., 2003, 87(2-3), 215-220.
[http://dx.doi.org/10.1016/S0378-8741(03)00149-1] [PMID: 12860311]
[125]
Benedek, B.; Kopp, B.; Melzig, M.F. Achillea millefolium L. s.l. -- is the anti-inflammatory activity mediated by protease inhibition? J. Ethnopharmacol., 2007, 113(2), 312-317.
[http://dx.doi.org/10.1016/j.jep.2007.06.014] [PMID: 17689902]
[126]
Ulubelen, A.; Öksüz, S.; Schuster, A. A sesquiterpene lactone from Achillea millefolium subsp. millefolium. Phytochemistry, 1990, 29(12), 3948-3955.
[http://dx.doi.org/10.1016/0031-9422(90)85371-L]
[127]
Rezaie, A.; Ahmadizadeh, C. Study of sedation, pre-anesthetic and anti-anxiety effects of polar, semi-polar and non-polar fractions of yarrow (Achillea millefolium) extract compared with Diazepam in rats. Life Sci. J., 2013, 10, 907-913.
[128]
Fedotova, J.; Kubatka, P.; Büsselberg, D.; Shleikin, A.G.; Caprnda, M.; Dragasek, J.; Rodrigo, L.; Pohanka, M.; Gasparova, I.; Nosal, V.; Opatrilova, R.; Qaradakhi, T.; Zulli, A.; Kruzliak, P. Therapeutical strategies for anxiety and anxiety-like disorders using plant-derived natural compounds and plant extracts. Biomed. Pharmacother., 2017, 95, 437-446.
[http://dx.doi.org/10.1016/j.biopha.2017.08.107] [PMID: 28863384]
[129]
Abbas, M.A.; Jaffal, S.M.; Al-Najjar, B.O. Analgesic and anxiolytic activities of Achillea biebersteinii: evidence for the involvement of GABAergic systems. Orient. J. Chem., 2019, 35(4), 1433-1442.
[http://dx.doi.org/10.13005/ojc/350426]
[130]
Zakeri, S. Achillea millefolium, L. as a recommendation for the management of hysteria. Trad. Integrat. Med., 2020, 5(1), 19-25.
[131]
Molina-Hernandez, M.; Tellez-Alcantara, N.P.; Diaz, M.A.; Perez Garcia, J.; Olivera Lopez, J.I.; Jaramillo, M.T. Anticonflict actions of aqueous extracts of flowers of Achillea millefolium L. vary according to the estrous cycle phases in Wistar rats. Phytother. Res., 2004, 18(11), 915-920.
[http://dx.doi.org/10.1002/ptr.1578] [PMID: 15597307]
[132]
Bendz, G.; Jönsson, B. Anthocyanins in leaves of Nymphaea candida. Phytochemistry, 1971, 10(2), 471-472.
[http://dx.doi.org/10.1016/S0031-9422(00)94083-4]
[133]
Khan, N.; Sultana, S. Anticarcinogenic effect of Nymphaea alba against oxidative damage, hyperproliferative response and renal carcinogenesis in Wistar rats. Mol. Cell. Biochem., 2005, 271(1-2), 1-11.
[http://dx.doi.org/10.1007/s11010-005-2258-2] [PMID: 15881650]
[134]
Jacob Jesurun, R.; Jagadeesh, S.; Ganesan, S.; Venugopala Rao, K.; Eerike, M. Anti inflammatory activity of ethanolic extract of Nymphaea alba flower in swiss albino mice. Int. J. Med. Res. Health Sci., 2013, 2(3), 474-478.
[135]
Bose, A.; Ray, S.D.; Sahoo, M. Evaluation of analgesic and antioxidant potential of ethanolic extract of Nymphaea alba rhizome. Oxid. Antioxid. Med. Sci., 2012, 1(3), 217-223.
[http://dx.doi.org/10.5455/oams.140912.or.017]
[136]
Madhusudhanan, N.; Lakshmi, T.; Kumar, G.; Ramakrishanan, K.V.; Roy, A.; Geetha, R. In vitro antioxidant and free radical scavenging activity of aqueous and ethanolic flower extract of Nymphaea alba. Int. J. Drug Dev. Res., 2011, 3(3), 252-258.
[137]
Bakr, R.O.; El-Naa, M.M.; Zaghloul, S.S.; Omar, M.M. Profile of bioactive compounds in Nymphaea alba L. leaves growing in Egypt: hepatoprotective, antioxidant and anti-inflammatory activity. BMC Complement. Altern. Med., 2017, 17(1), 52-60.
[http://dx.doi.org/10.1186/s12906-017-1561-2] [PMID: 28095910]
[138]
Aduema, W.; Munachi, I.; Akunneh-Wariso, C. Effect of ethanol extract leaves of Nymphaea lotus (Water Lily) on fear and anxiety behaviour in mice. Ann. Clin. Lab. Res., 2018, 6(1), 223-225.
[139]
Aduema, W.; Akunneh-Wariso, C.; Amah, A. Evaluation of the anxiolytic activity of the leaves of Nymphaea lotus (Water Lily) in mice. Biol. Med. Case Rep., 2018, 2(1), 15-18.
[140]
Thippeswamy, B.S.; Mishra, B.; Veerapur, V.P.; Gupta, G. Anxiolytic activity of Nymphaea alba Linn. in mice as experimental models of anxiety. Indian J. Pharmacol., 2011, 43(1), 50-55.
[http://dx.doi.org/10.4103/0253-7613.75670] [PMID: 21455422]
[141]
Wojtyniak, K.; Szymański, M.; Matławska, I. Leonurus cardiaca L. (motherwort): a review of its phytochemistry and pharmacology. Phytother. Res., 2013, 27(8), 1115-1120.
[http://dx.doi.org/10.1002/ptr.4850] [PMID: 23042598]
[142]
Peng, Y.; Zheng, C.; Wang, Y.N.; Dai, O. Novel labdane diterpenoids from the aerial parts of Leonurus japonicus. Phytochem. Lett., 2017, 20, 45-48.
[http://dx.doi.org/10.1016/j.phytol.2017.04.002]
[143]
Miłkowska-Leyck, K.; Filipek, B.; Strzelecka, H. Pharmacological effects of lavandulifolioside from Leonurus cardiaca. J. Ethnopharmacol., 2002, 80(1), 85-90.
[http://dx.doi.org/10.1016/S0378-8741(02)00016-8] [PMID: 11891090]
[144]
Song, X.; Wang, T.; Zhang, Z.; Jiang, H.; Wang, W.; Cao, Y.; Zhang, N. Leonurine exerts anti-inflammatory effect by regulating inflammatory signaling pathways and cytokines in LPS-induced mouse mastitis. Inflammation, 2015, 38(1), 79-88.
[http://dx.doi.org/10.1007/s10753-014-0009-9] [PMID: 25189466]
[145]
Xu, D.; Chen, M.; Ren, X.; Ren, X.; Wu, Y. Leonurine ameliorates LPS-induced acute kidney injury via suppressing ROS-mediated NF-κB signaling pathway. Fitoterapia, 2014, 97, 148-155.
[http://dx.doi.org/10.1016/j.fitote.2014.06.005] [PMID: 24924288]
[146]
Ritter, M.; Melichar, K.; Strahler, S.; Kuchta, K.; Schulte, J.; Sartiani, L.; Cerbai, E.; Mugelli, A.; Mohr, F.W.; Rauwald, H.W.; Dhein, S. Cardiac and electrophysiological effects of primary and refined extracts from Leonurus cardiaca L. (Ph.Eur.). Planta Med., 2010, 76(6), 572-582.
[http://dx.doi.org/10.1055/s-0029-1240602] [PMID: 19918711]
[147]
Shin, H.Y.; Kim, S.H.; Kang, S.M.; Chang, I.J.; Kim, S.Y.; Jeon, H.; Leem, K.H.; Park, W.H.; Lim, J.P.; Shin, T.Y. Anti-inflammatory activity of Motherwort (Leonurus sibiricus L.). Immunopharmacol. Immunotoxicol., 2009, 31(2), 209-213.
[http://dx.doi.org/10.1080/08923970802135443] [PMID: 19514995]
[148]
Ebrahimzadeh, M.; Nabavi, S.; Nabavi, S.; Eslami, B.; Asgarirad, H. In vitro antioxidant and free radical scavenging activity of Leonurus cardiaca subsp. Persicus, Grammosciadium platycarpum and Onosma demawendicum. Afr. J. Biotechnol., 2010, 9(51), 8865-8871.
[149]
Sadowska, B.; Micota, B.; Różalski, M.; Redzynia, M.; Różalski, M. The immunomodulatory potential of Leonurus cardiaca extract in relation to endothelial cells and platelets. Innate Immun., 2017, 23(3), 285-295.
[http://dx.doi.org/10.1177/1753425917691116] [PMID: 28142301]
[150]
Rauwald, H.; Kuchta, K.; Savtschenko, A.; Brückner, A.; Rusch, C.; Appel, K. GABAA receptor binding assays of standardized Leonurus cardiaca and L. japonicus extracts as well as their isolated constituents. Planta Med., 2013, 79(13), 1103-1110.
[http://dx.doi.org/10.1055/s-0033-1352395]
[151]
Shikov, A.N.; Pozharitskaya, O.N.; Makarov, V.G.; Demchenko, D.V.; Shikh, E.V. Effect of Leonurus cardiaca oil extract in patients with arterial hypertension accompanied by anxiety and sleep disorders. Phytother. Res., 2011, 25(4), 540-543.
[http://dx.doi.org/10.1002/ptr.3292] [PMID: 20839214]
[152]
Wang, X.C.; Zhao, Q.Y.; Ma, C.L.; Zhang, Z.H.; Cao, H.L.; Kong, Y.M.; Yue, C.; Hao, X.Y.; Chen, L.; Ma, J.Q.; Jin, J.Q.; Li, X.; Yang, Y.J. Global transcriptome profiles of Camellia sinensis during cold acclimation. BMC Genomics, 2013, 14(1), 415-420.
[http://dx.doi.org/10.1186/1471-2164-14-415] [PMID: 23799877]
[153]
Punyasiri, P.A.; Abeysinghe, I.S.; Kumar, V.; Treutter, D.; Duy, D.; Gosch, C.; Martens, S.; Forkmann, G.; Fischer, T.C. Flavonoid biosynthesis in the tea plant Camellia sinensis: properties of enzymes of the prominent epicatechin and catechin pathways. Arch. Biochem. Biophys., 2004, 431(1), 22-30.
[http://dx.doi.org/10.1016/j.abb.2004.08.003] [PMID: 15464723]
[154]
Ferrara, L.; Montesano, D.; Senatore, A. The distribution of minerals and flavonoids in the tea plant (Camellia sinensis). Farmaco, 2001, 56(5-7), 397-401.
[http://dx.doi.org/10.1016/S0014-827X(01)01104-1] [PMID: 11482766]
[155]
Weeks, B.S. Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action. Relarian. Med. Sci. Monit., 2009, 15(11), RA256-RA262.
[PMID: 19865069]
[156]
Boehm, K.; Borrelli, F.; Ernst, E.; Habacher, G.; Hung, S.K.; Milazzo, S.; Horneber, M. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst. Rev., 2009, 2(3), CD005004.
[http://dx.doi.org/10.1002/14651858.CD005004.pub2] [PMID: 19588362]
[157]
Kumar, A.; Mazumder, A.; Saravanan, V. Antihyperlipidemic activity of Camellia sinensis leaves in triton wr-1339 induced albino rats. Pharmacogn. Mag., 2008, 4(13), 60-64.
[158]
Nantz, M.P.; Rowe, C.A.; Bukowski, J.F.; Percival, S.S. Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition, 2009, 25(2), 147-154.
[http://dx.doi.org/10.1016/j.nut.2008.07.018] [PMID: 18848434]
[159]
Brown, M.D. Green tea (Camellia sinensis) extract and its possible role in the prevention of cancer. Altern. Med. Rev., 1999, 4(5), 360-370.
[PMID: 10559550]
[160]
Kurihara, H.; Shibata, H.; Fukui, Y.; Kiso, Y.; Xu, J.K.; Yao, X.S.; Fukami, H. Evaluation of the hypolipemic property of Camellia sinensis Var. ptilophylla on postprandial hypertriglyceridemia. J. Agric. Food Chem., 2006, 54(14), 4977-4981.
[http://dx.doi.org/10.1021/jf0603681] [PMID: 16819905]
[161]
Mangal, A.; Jain, V.; Amit, J.; Jat, R.; Bharadwaj, S.; Suman, J. Antianxiety activity of leaves of Camellia sinensis. J. Pharm. Res., 2010, 3(3), 605-607.
[162]
Shastry, R.; Ullal, S.D.; Karkala, S.; Rai, S.; Gadgade, A. Anxiolytic activity of aqueous extract of Camellia sinensis in rats. Indian J. Pharmacol., 2016, 48(6), 681-686.
[http://dx.doi.org/10.4103/0253-7613.194864] [PMID: 28066107]
[163]
Tabassum, I.; Siddiqui, Z.N.; Rizvi, S.J. Effects of Ocimum sanctum and Camellia sinensis on stress-induced anxiety and depression in male albino Rattus norvegicus. Indian J. Pharmacol., 2010, 42(5), 283-288.
[http://dx.doi.org/10.4103/0253-7613.70108] [PMID: 21206619]
[164]
Kumar, S.; Madaan, R.; Sharma, A. Pharmacological evaluation of bioactive principle of Turnera aphrodisiaca. Indian J. Pharm. Sci., 2008, 70(6), 740-744.
[http://dx.doi.org/10.4103/0250-474X.49095] [PMID: 21369434]
[165]
Kalimuthu, K.; Prabakaran, R.; Preetha, V. phytochemical screening and GC-MS studies on the ethanolic extract of Turnera Ulmifolia L. Inter. J. Pharmaceut. Phytopharmacol. Res., 2017, 4(3), 179-181.
[166]
Kumar, S.; Madaan, R.; Sharma, A. Estimation of apigenin, an anxiolytic constituent, in Turnera aphrodisiaca. Indian J. Pharm. Sci., 2008, 70(6), 847-851.
[167]
Kumar, S.; Sharma, A. Apigenin: the anxiolytic constituent of Turnera aphrodisiaca. Pharm. Biol., 2006, 44(2), 84-90.
[http://dx.doi.org/10.1080/13880200600591758]
[168]
Kumar, S.; Sharma, A. Anti-anxiety activity studies of various extracts of Turnera aphrodisiaca Ward. J. Herb. Pharmacother., 2005, 5(4), 13-21.
[http://dx.doi.org/10.1080/J157v05n04_02] [PMID: 16635964]
[169]
Kumar, S.; Sharma, A. Anti-anxiety activity studies on homoeopathic formulations of Turnera aphrodisiaca Ward. Evid. Based Complement. Alternat. Med., 2005, 2(1), 117-119.
[http://dx.doi.org/10.1093/ecam/neh069] [PMID: 15864356]
[170]
Kumar, S.; Madaan, R.; Sharma, A. Evaluation of aphrodisiac activity of Turnera aphrodisiaca. Inter. J. Pharm. Phytochem. Res., 2009, 1, 1-4.
[171]
Kolodziej, H.; Ferreira, D.; Roux, D.G. Synthesis of condensed tannins. Part 12. Direct access to 4, 6-and4, 8-all-2, 3-cis-procyanidin derivatives from (–)-epicatechin: assessment of bonding positions in oligomeric analogues from Crataegus oxyacantha L. J. Chem. Soc., 1984, 4(5), 343-350.
[172]
Kashyap, C.; Arya, V.; Thakur, N. Ethnomedicinal and phytopharmacological potential of Crataegus oxyacantha Linn.–A review. Asian Pac. J. Trop. Biomed., 2012, 2(2), 1194-1199.
[http://dx.doi.org/10.1016/S2221-1691(12)60383-9]
[173]
al Makdessi, S.; Sweidan, H.; Dietz, K.; Jacob, R. Protective effect of Crataegus oxyacantha against reperfusion arrhythmias after global no-flow ischemia in the rat heart. Basic Res. Cardiol., 1999, 94(2), 71-77.
[http://dx.doi.org/10.1007/s003950050128] [PMID: 10326654]
[174]
Kim, S.H.; Kang, K.W.; Kim, K.W.; Kim, N.D. Procyanidins in crataegus extract evoke endothelium-dependent vasorelaxation in rat aorta. Life Sci., 2000, 67(2), 121-131.
[http://dx.doi.org/10.1016/S0024-3205(00)00608-1] [PMID: 10901280]
[175]
Rastogi, S.; Pandey, M.M.; Rawat, A.K. Traditional herbs: a remedy for cardiovascular disorders. Phytomedicine, 2016, 23(11), 1082-1089.
[http://dx.doi.org/10.1016/j.phymed.2015.10.012] [PMID: 26656228]
[176]
Verma, S.; Jain, V.; Verma, D.; Khamesra, R. Crataegus oxyacantha—a cardioprotective herb. J. Herb. Med. Toxicol., 2007, 1(1), 65-71.
[177]
Kostić, D.A.; Velicković, J.M.; Mitić, S.S.; Mitić, M.N.; Randelović, S.S. Phenolic content, and antioxidant and antimicrobial activities of Crataegus oxyacantha L (Rosaceae) fruit extract from Southeast Serbia. Trop. J. Pharm. Res., 2012, 11(1), 117-124.
[http://dx.doi.org/10.4314/tjpr.v11i1.15]
[178]
Hanus, M.; Lafon, J.; Mathieu, M. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr. Med. Res. Opin., 2004, 20(1), 63-71.
[http://dx.doi.org/10.1185/030079903125002603] [PMID: 14741074]
[179]
Dragull, K.; Yoshida, W.Y.; Tang, C.S. Piperidine alkaloids from Piper methysticum. Phytochemistry, 2003, 63(2), 193-198.
[http://dx.doi.org/10.1016/S0031-9422(03)00111-0] [PMID: 12711141]
[180]
Gleitz, J.; Beile, A.; Wilkens, P.; Ameri, A.; Peters, T. Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets. Planta Med., 1997, 63(1), 27-30.
[http://dx.doi.org/10.1055/s-2006-957597] [PMID: 9063093]
[181]
Robinson, V.; Bergfeld, W.F.; Belsito, D.V.; Klaassen, C.D.; Marks, J.G., Jr; Shank, R.C.; Slaga, T.J.; Snyder, P.W.; Andersen, F.A. Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of Piper methysticum leaf/root/stem extract and Piper methysticum root extract. Int. J. Toxicol., 2009, 28(6)(Suppl.), 175S-188S.
[http://dx.doi.org/10.1177/10915818093509341] [PMID: 19966149]
[182]
Escher, M.; Desmeules, J.; Giostra, E.; Mentha, G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ, 2001, 322(7279), 139.
[http://dx.doi.org/10.1136/bmj.322.7279.139] [PMID: 11159570]
[183]
Kretzschmar, R.; Meyer, H.J. Comparative studies on the anticonvulsant activity of the pyrone compounds of Piper methysticum Forst. Arch. Int. Pharmacodyn. Ther., 1969, 177(2), 261-267.
[PMID: 5807167]
[184]
Feltenstein, M.W.; Lambdin, L.C.; Ganzera, M.; Ranjith, H.; Dharmaratne, W.; Nanayakkara, N.P.; Khan, I.A.; Sufka, K.J. Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social-separation-stress procedure. Phytother. Res., 2003, 17(3), 210-216.
[http://dx.doi.org/10.1002/ptr.1107] [PMID: 12672148]
[185]
Garrett, K.M.; Basmadjian, G.; Khan, I.A.; Schaneberg, B.T.; Seale, T.W. Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice. Psychopharmacology (Berl.), 2003, 170(1), 33-41.
[http://dx.doi.org/10.1007/s00213-003-1520-0] [PMID: 12845414]
[186]
Rex, A.; Morgenstern, E.; Fink, H. Anxiolytic-like effects of kava-kava in the elevated plus maze test--a comparison with diazepam. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2002, 26(5), 855-860.
[http://dx.doi.org/10.1016/S0278-5846(01)00330-X] [PMID: 12369257]
[187]
Lehmann, E.; Kinzler, E.; Friedemann, J. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A double-blind placebo-controlled study of four weeks treatment. Phytomedicine, 1996, 3(2), 113-119.
[http://dx.doi.org/10.1016/S0944-7113(96)80024-9] [PMID: 23194958]
[188]
Perna, G.; Guerriero, G.; Caldirola, D. Emerging drugs for panic disorder. Expert Opin. Emerg. Drugs, 2011, 16(4), 631-645.
[http://dx.doi.org/10.1517/14728214.2011.628313] [PMID: 21999303]
[189]
Robbins, T.W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl.), 2002, 163(3-4), 362-380.
[http://dx.doi.org/10.1007/s00213-002-1154-7] [PMID: 12373437]
[190]
Mairaje, A.V.; Prabhu, P.; Kamath, J.V. recent advances in cannabis addiction and rehabilitation: a review. Crit. Rev. Phys. Rehabil. Med., 2016, 28(1-2), 57-76.
[http://dx.doi.org/10.1615/CritRevPhysRehabilMed.2016019200]
[191]
Uribe-Mariño, A.; Francisco, A.; Castiblanco-Urbina, M.A.; Twardowschy, A.; Salgado-Rohner, C.J.; Crippa, J.A.; Hallak, J.E.; Zuardi, A.W.; Coimbra, N.C. Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology, 2012, 37(2), 412-421.
[http://dx.doi.org/10.1038/npp.2011.188] [PMID: 21918503]
[192]
Masataka, N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front. Psychol., 2019, 10(1), 2466.
[http://dx.doi.org/10.3389/fpsyg.2019.02466] [PMID: 31787910]
[193]
Skelley, J.W.; Deas, C.M.; Curren, Z.; Ennis, J. Use of cannabidiol in anxiety and anxiety-related disorders. J. Am. Pharm. Assoc. (2003), 2020, 60(1), 253-261.
[http://dx.doi.org/10.1016/j.japh.2019.11.008] [PMID: 31866386]
[194]
Sharpe, L.; Sinclair, J.; Kramer, A.; de Manincor, M.; Sarris, J. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J. Transl. Med., 2020, 18(1), 374.
[http://dx.doi.org/10.1186/s12967-020-02518-2] [PMID: 33008420]
[195]
Twardowschy, A.; Castiblanco-Urbina, M.A.; Uribe-Mariño, A.; Biagioni, A.F.; Salgado-Rohner, C.J.; Crippa, J.A.; Coimbra, N.C. The role of 5-HT1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae). J. Psychopharmacol., 2013, 27(12), 1149-1159.
[http://dx.doi.org/10.1177/0269881113493363] [PMID: 23926240]
[196]
Ribeiro Severo, A.I.; Ilva Filho, A.E.J. Generalized anxiety: a systematic review Passiflora incarnata (passion fruit), Matricaria recutita (Chamomile) and Melissa officinalis (lemongrass). Inter. J. Family Community Med., 2019, 3(5), 200-208.
[197]
Ozsavci, D.; Ozakpinar, O.B.; Cetin, M.; Aricioglu, F. Level of clinical evidence of herbal complementary therapies in psychiatric disorders. Psychiat. Clin. Psychopharmacol., 2019, 29(3), 239-243.
[http://dx.doi.org/10.1080/24750573.2019.1625587]
[198]
Pittler, M.H.; Ernst, E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J. Clin. Psychopharmacol., 2000, 20(1), 84-89.
[http://dx.doi.org/10.1097/00004714-200002000-00014] [PMID: 10653213]
[199]
Sarris, J.; Stough, C.; Bousman, C.A.; Wahid, Z.T.; Murray, G.; Teschke, R.; Savage, K.M.; Dowell, A.; Ng, C.; Schweitzer, I. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J. Clin. Psychopharmacol., 2013, 33(5), 643-648.
[http://dx.doi.org/10.1097/JCP.0b013e318291be67] [PMID: 23635869]
[200]
Connor, K.M.; Davidson, J.R. A placebo-controlled study of Kava kava in generalized anxiety disorder. Int. Clin. Psychopharmacol., 2002, 17(4), 185-188.
[http://dx.doi.org/10.1097/00004850-200207000-00005] [PMID: 12131602]
[201]
Stickel, F.; Baumüller, H.M.; Seitz, K.; Vasilakis, D.; Seitz, G.; Seitz, H.K.; Schuppan, D. Hepatitis induced by Kava (Piper methysticum rhizoma). J. Hepatol., 2003, 39(1), 62-67.
[http://dx.doi.org/10.1016/S0168-8278(03)00175-2] [PMID: 12821045]
[202]
Wolfson, P.; Hoffmann, D.L. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern. Ther. Health Med., 2003, 9(2), 74-78.
[PMID: 12652886]
[203]
Akhondzadeh, S.; Naghavi, H.R.; Vazirian, M.; Shayeganpour, A.; Rashidi, H.; Khani, M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J. Clin. Pharm. Ther., 2001, 26(5), 363-367.
[http://dx.doi.org/10.1046/j.1365-2710.2001.00367.x] [PMID: 11679026]
[204]
Movafegh, A.; Alizadeh, R.; Hajimohamadi, F.; Esfehani, F.; Nejatfar, M. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth. Analg., 2008, 106(6), 1728-1732.
[http://dx.doi.org/10.1213/ane.0b013e318172c3f9] [PMID: 18499602]
[205]
Miyasaka, L.S.; Atallah, A.N.; Soares, B.G. Passiflora for anxiety disorder. Cochrane Database Syst. Rev., 2007, 24(1), CD004518.
[PMID: 17253512]
[206]
Amsterdam, J.D.; Li, Y.; Soeller, I.; Rockwell, K.; Mao, J.J.; Shults, J. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J. Clin. Psychopharmacol., 2009, 29(4), 378-382.
[http://dx.doi.org/10.1097/JCP.0b013e3181ac935c] [PMID: 19593179]
[207]
Woelk, H.; Arnoldt, K.H.; Kieser, M.; Hoerr, R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J. Psychiatr. Res., 2007, 41(6), 472-480.
[http://dx.doi.org/10.1016/j.jpsychires.2006.05.004] [PMID: 16808927]
[208]
Kobak, K.A.; Taylor, L.V.; Bystritsky, A.; Kohlenberg, C.J.; Greist, J.H.; Tucker, P.; Warner, G.; Futterer, R.; Vapnik, T. St John’s wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int. Clin. Psychopharmacol., 2005, 20(6), 299-304.
[http://dx.doi.org/10.1097/00004850-200511000-00003] [PMID: 16192837]
[209]
Sayyah, M.; Boostani, H.; Pakseresht, S.; Malaieri, A. Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(8), 1513-1516.
[http://dx.doi.org/10.1016/j.pnpbp.2009.08.021] [PMID: 19737592]
[210]
Kobak, K.A.; Taylor, L.V.; Warner, G.; Futterer, R.St. John’s wort versus placebo in social phobia: results from a placebo-controlled pilot study. J. Clin. Psychopharmacol., 2005, 25(1), 51-58.
[http://dx.doi.org/10.1097/01.jcp.0000150227.61501.00] [PMID: 15643100]
[211]
Saeed, S.A.; Bloch, R.M.; Antonacci, D.J. Herbal and dietary supplements for treatment of anxiety disorders. Am. Fam. Physician, 2007, 76(4), 549-556.
[PMID: 17853630]
[212]
Buszewicz, M.; Griffin, M.; McMahon, E.M.; Beecham, J.; King, M. Evaluation of a system of structured, pro-active care for chronic depression in primary care: a randomised controlled trial. BMC Psychiatry, 2010, 10(1), 61-65.
[http://dx.doi.org/10.1186/1471-244X-10-61] [PMID: 20684786]
[213]
Dhawan, K.; Kumar, S.; Sharma, A. Anxiolytic activity of aerial and underground parts of Passiflora incarnata. Fitoterapia, 2001, 72(8), 922-926.
[http://dx.doi.org/10.1016/S0367-326X(01)00322-7] [PMID: 11731118]
[214]
Kinzler, E.; Krömer, J.; Lehmann, E. Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks. Arzneimittelforschung, 1991, 41(6), 584-588.
[PMID: 1930344]
[215]
Sarris, J.; Kavanagh, D.J. Kava and St. John’s Wort: current evidence for use in mood and anxiety disorders. J. Altern. Complement. Med., 2009, 15(8), 827-836.
[http://dx.doi.org/10.1089/acm.2009.0066] [PMID: 19614563]
[216]
Lotito, S.B.; Zhang, W.J.; Yang, C.S.; Crozier, A.; Frei, B. Metabolic conversion of dietary flavonoids alters their anti-inflammatory and antioxidant properties. Free Radic. Biol. Med., 2011, 51(2), 454-463.
[http://dx.doi.org/10.1016/j.freeradbiomed.2011.04.032] [PMID: 21571063]
[217]
Barnes, E.C.; Kumar, R.; Davis, R.A. The use of isolated natural products as scaffolds for the generation of chemically diverse screening libraries for drug discovery. Nat. Prod. Rep., 2016, 33(3), 372-381.
[http://dx.doi.org/10.1039/C5NP00121H] [PMID: 26739749]
[218]
Chorpita, B.F.; Daleiden, E.L.; Park, A.L.; Ward, A.M.; Levy, M.C.; Cromley, T.; Chiu, A.W.; Letamendi, A.M.; Tsai, K.H.; Krull, J.L. Child STEPs in California: A cluster randomized effectiveness trial comparing modular treatment with community implemented treatment for youth with anxiety, depression, conduct problems, or traumatic stress. J. Consult. Clin. Psychol., 2017, 85(1), 13-25.
[http://dx.doi.org/10.1037/ccp0000133] [PMID: 27548030]
[219]
Sammons, H.M.; Gubarev, M.I.; Krepkova, L.V.; Bortnikova, V.V.; Corrick, F.; Job, K.M.; Sherwin, C.M.; Enioutina, E.Y. European Union and Russia. Herbal medicines: challenges in the modern world. Part 2. Expert Rev. Clin. Pharmacol., 2016, 9(8), 1117-1127.
[http://dx.doi.org/10.1080/17512433.2016.1189326] [PMID: 27171366]
[220]
Miraglia, M.; Marvin, H.J.; Kleter, G.A.; Battilani, P.; Brera, C.; Coni, E.; Cubadda, F.; Croci, L.; De Santis, B.; Dekkers, S.; Filippi, L.; Hutjes, R.W.; Noordam, M.Y.; Pisante, M.; Piva, G.; Prandini, A.; Toti, L.; van den Born, G.J.; Vespermann, A. Climate change and food safety: an emerging issue with special focus on Europe. Food Chem. Toxicol., 2009, 47(5), 1009-1021.
[http://dx.doi.org/10.1016/j.fct.2009.02.005] [PMID: 19353812]
[221]
Sarris, J.; Panossian, A.; Schweitzer, I.; Stough, C.; Scholey, A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur. Neuropsychopharmacol., 2011, 21(12), 841-860.
[http://dx.doi.org/10.1016/j.euroneuro.2011.04.002] [PMID: 21601431]
[222]
Aruoma, O.I. Free radicals, oxidative stress, and antioxidants in human health and disease. J. Am. Oil Chem. Soc., 1998, 75(2), 199-212.
[http://dx.doi.org/10.1007/s11746-998-0032-9] [PMID: 32287334]
[223]
Xu, Y.; Wang, C.; Klabnik, J.J.; O’Donnell, J.M. Novel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment. Curr. Neuropharmacol., 2014, 12(2), 108-119.
[http://dx.doi.org/10.2174/1570159X11666131120231448] [PMID: 24669206]
[224]
de Oliveira, M.R.; Silvestrin, R.B.; Mello, E.; Souza, T.; Moreira, J.C. Oxidative stress in the hippocampus, anxiety-like behavior and decreased locomotory and exploratory activity of adult rats: effects of sub acute vitamin A supplementation at therapeutic doses. Neurotoxicology, 2007, 28(6), 1191-1199.
[http://dx.doi.org/10.1016/j.neuro.2007.07.008] [PMID: 17727954]
[225]
Pham-Huy, L.A.; He, H.; Pham-Huy, C. Free radicals, antioxidants in disease and health. Int. J. Biomed. Sci., 2008, 4(2), 89-96.
[PMID: 23675073]
[226]
Shafeen, S.; Srinath, R.; Arafath, S.; Nagarjuna, S.; Padmanabha, R. Evaluation of antianxiety and antidepressant activity of Cassia occidentalis leaves. Asian J. Pharm. Clin. Res., 2012, 3(1), 47-50.
[227]
Hajhashemi, V.; Rabbani, M.; Ghanadi, A.; Davari, E. Evaluation of antianxiety and sedative effects of essential oil of Ducrosia anethifolia in mice. Clinics (São Paulo), 2010, 65(10), 1037-1042.
[http://dx.doi.org/10.1590/S1807-59322010001000020] [PMID: 21120308]
[228]
Yadav, A.V.; Kawale, L.A.; Nade, V.S. Effect of Morus alba L. (mulberry) leaves on anxiety in mice. Indian J. Pharmacol., 2008, 40(1), 32-36.
[http://dx.doi.org/10.4103/0253-7613.40487] [PMID: 21264159]
[229]
de Oliveira, A.M.; Mesquita, M.S.; da Silva, G.C.; de Oliveira Lima, E.; de Medeiros, P.L.; Paiva, P.M.; de Souza, I.A.; Napoleão, T.H. Evaluation of toxicity and antimicrobial activity of an ethanolic extract from leaves of Morus alba L.(Moraceae). Evid. Based Complement. Alternat. Med., 2015, 2015(5), 513978.
[http://dx.doi.org/10.1155/2015/513978] [PMID: 26246840]
[230]
Aguirre-Hernández, E.; Martínez, A.L.; González-Trujano, M.E.; Moreno, J.; Vibrans, H.; Soto-Hernández, M. Pharmacological evaluation of the anxiolytic and sedative effects of Tilia americana L. var. mexicana in mice. J. Ethnopharmacol., 2007, 109(1), 140-145.
[http://dx.doi.org/10.1016/j.jep.2006.07.017] [PMID: 16930893]
[231]
Aguirre-Hernández, E.; Rosas-Acevedo, H.; Soto-Hernández, M.; Martínez, A.L.; Moreno, J.; González-Trujano, M.E. Bioactivity-guided isolation of β-sitosterol and some fatty acids as active compounds in the anxiolytic and sedative effects of Tilia americana var. mexicana. Planta Med., 2007, 73(11), 1148-1155.
[http://dx.doi.org/10.1055/s-2007-981593] [PMID: 17823876]
[232]
Juarez-Flores, B.; Jimenez-Capdeville, M.; Ortiz-Perez, M. Anxiolytic and sedative effects of essential oil from Casimiroa pringlei on Wistar rats. J. Med. Plants Res., 2009, 3(10), 791-798.
[233]
Emamghoreishi, M.; Khasaki, M.; Aazam, M.F. Coriandrum sativum: evaluation of its anxiolytic effect in the elevated plus-maze. J. Ethnopharmacol., 2005, 96(3), 365-370.
[http://dx.doi.org/10.1016/j.jep.2004.06.022] [PMID: 15619553]
[234]
Sreelatha, S.; Padma, P.R.; Umadevi, M. Protective effects of Coriandrum sativum extracts on carbon tetrachloride-induced hepatotoxicity in rats. Food Chem. Toxicol., 2009, 47(4), 702-708.
[http://dx.doi.org/10.1016/j.fct.2008.12.022] [PMID: 19146910]
[235]
Dhayabaran, D.; Florance, E.J.; Puratchikody, A. Anxiolytic and anticonvulsant activity of alcoholic extract of heart wood of Cedrus deodara roxb. in rodents. J. Med. Plants Res., 2013, 4(14), 1374-1381.
[236]
Gadekar, D.; Sourabh, J.; Jitender, M. Evaluation of anxiolytic activity of Boerhaavia diffusa hydro-alcoholic extract of leaves in rats. Inter. Res. J. Pharm., 2011, 2, 90-92.
[237]
Kishore, R.N.; Anjaneyulu, N.; Ganesh, M.N.; Sravya, N. Evaluation of anxiolytic activity of ethanolic extract of Foeniculum vulgare in mice model. Int. J. Pharm. Pharm. Sci., 2012, 4(3), 584-586.
[238]
Avijit, C.; Amudha, P.; Geetha, M.; Singh, N. Evaluation of anxiolytic activity of methanolic extract of Sapindus mukorossi Gaertn. in mice. Int. J. Pharma Bio Sci., 2010, 1(3), 90-100.
[239]
Doukkali, Z.; Taghzouti, K.; Bouidida, E.L.; Nadjmouddine, M.; Cherrah, Y.; Alaoui, K. Evaluation of anxiolytic activity of methanolic extract of Urtica urens in a mice model. Behav. Brain Funct., 2015, 11(1), 19-25.
[http://dx.doi.org/10.1186/s12993-015-0063-y] [PMID: 25902868]
[240]
Ayoka, A.; Akomolafe, R.; Iwalewa, E.; Ukponmwan, O.E. Studies on the anxiolytic effect of Spondias mombin L. (Anacardiaceae) extracts. Afr. J. Tradit. Complement. Altern. Med., 2006, 2(2), 153-165.
[241]
Bora, K.S.; Dubey, A. Evaluation of anti-anxiety activity of Melissa parviflora (Benth.) in rats. Thaiphesatchasan, 2015, 39(3), 70-75.
[242]
Garg, V.; Dhar, V.; Sharma, A.; Dutt, R. Antianxiety activity of methanol extract of Gelsemium sempervirens (Linn.). Ait. J. Stress Physiol. Biochem., 2012, 8(2), 118-124.
[243]
Saha, A.; Bose, S.; Banerjee, S. Anti-anxiety activity of Amorphophallus paeoniifolius tuber in mice. J. Pharm. Res., 2013, 6(7), 748-752.
[http://dx.doi.org/10.1016/j.jopr.2013.07.018]
[244]
Manjunatha, S. Evaluation of anti-depressent activity of ethanol extract of Drypetus roxburgii. J. Pharm. Biol. Sci., 2016, 11(6), 28-31.
[245]
Kiessoun, K. Evaluation of the anxiolytic effect of the methanol stem extracts of Cissus quadrangularis. J. Coast. Life Med., 2013, 1(4), 287-292.
[246]
Ganu, G.; Garud, A.; Agarwal, V.; Suralkar, U.; Jadhav, S.; Kshirsagar, A. Anti-anxiety activity of Mimusops elengi barks extract in experimental animals. Res. J. Pharm. Biol. Chem. Sci., 2011, 2, 405-410.
[247]
Marques, T.C.; Melo, C.H.; Freitas, R.M. In vitro evaluation of antioxidant, anxiolytic and antidepressant-like effects of the Bellis perennis extract. Rev. Bras. Farmacogn., 2012, 22(5), 1044-1052.
[http://dx.doi.org/10.1590/S0102-695X2012005000082]
[248]
Barua, C.C.; Begum, S.A.; Barua, A.G.; Borah, R.S.; Lahkar, M. Anxiolytic and anticonvulsant activity of methanol extract of leaves of Alternanthera brasiliana (L.) Kuntze (Amaranthaceae) in laboratory animals. Indian J. Exp. Biol., 2013, 51(6), 450-457.
[PMID: 23926693]
[249]
Olayiwola, G.; Ukponmwan, O.; Olawode, D. Sedative and anxiolytic effects of the extracts of the leaves of Stachytarpheta cayennensis in mice. Afr. J. Tradit. Complement. Altern. Med., 2013, 10(6), 568-579.
[http://dx.doi.org/10.4314/ajtcam.v10i6.32] [PMID: 24311890]
[250]
Khalid, M.S.; Abrar, S.; Khan, H. Anti-anxiety effect on ethanolic extracts of Agave americana Linn. Asian J. Pharmaceut. Clin. Res., 2013, 6(1), 43-48.
[251]
Sachan, A.; Kumar, S.; Singh, H.; Shankar, P.; Kumar, D.; Sachan, A.K. Potential anti-anxiety effect of Mucuna pruriens in experimental model of swiss albino mice. Pharmacol. Toxicol. Biomed. Rep., 2015, 1(1), 20-23.
[http://dx.doi.org/10.5530/PTB.1.1.7]
[252]
Deepshikha, A.; Khare, P.; Singh, L.; Chauhan, S. Evaluation of antianxiety activity of Bauhinia variegata by light-dark test of mice. J. Toxicol. Sci., 2016, 8(4), 144-147.
[253]
Gupta, V.; Bansal, P.; Kohli, K.; Ghaiye, P. Anxiolytic effect of Citrus paradisi var. Marsh seedless using different models. Int. Neuropsychiatr. Dis. J., 2015, 4(3), 108-113.
[http://dx.doi.org/10.9734/INDJ/2015/18699]
[254]
Kumar, D.; Dhobi, M. Antianxiety and antioxidant profile of blue and white variety of Clitoria ternatea L. Ind. J. Res. Pharm. Biotechnol., 2016, 4(3), 90-94.
[255]
Generoso, M.B.; Soares, A.; Taiar, I.T.; Cordeiro, Q.; Shiozawa, P. Lavender oil preparation (Silexan) for treating anxiety: an updated meta-analysis. J. Clin. Psychopharmacol., 2017, 37(1), 115-117.
[http://dx.doi.org/10.1097/JCP.0000000000000615] [PMID: 27861196]
[256]
Lakhan, S.E.; Vieira, K.F. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr. J., 2010, 9(1), 42-45.
[http://dx.doi.org/10.1186/1475-2891-9-42] [PMID: 20929532]
[257]
Pratte, M.A.; Nanavati, K.B.; Young, V.; Morley, C.P. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). J. Altern. Complement. Med., 2014, 20(12), 901-908.
[http://dx.doi.org/10.1089/acm.2014.0177] [PMID: 25405876]
[258]
Sarris, J.; McIntyre, E.; Camfield, D.A. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs, 2013, 27(4), 301-319.
[http://dx.doi.org/10.1007/s40263-013-0059-9] [PMID: 23653088]
[259]
Ernst, E. Herbal remedies for anxiety - a systematic review of controlled clinical trials. Phytomedicine, 2006, 13(3), 205-208.
[http://dx.doi.org/10.1016/j.phymed.2004.11.006] [PMID: 16428031]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy